Get the Stockscreener App
4.67
1.52%
0.07
After Hours:
4.74
0.07
+1.50%
Opus Genetics Inc stock is traded at $4.67, with a volume of 2.24M.
It is up +1.52% in the last 24 hours and up +25.88% over the past month.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
See More
Previous Close:
$4.60
Open:
$4.53
24h Volume:
2.24M
Relative Volume:
2.39
Market Cap:
$388.52M
Revenue:
$14.20M
Net Income/Loss:
$-49.59M
P/E Ratio:
-5.5437
EPS:
-0.8424
Net Cash Flow:
$-35.25M
1W Performance:
+26.56%
1M Performance:
+25.88%
6M Performance:
+2.19%
1Y Performance:
+264.84%
1-Day Range:
$4.40
$4.80
1-Week Range:
$3.511
$4.83
52-Week Range:
$1.24
$5.81
Opus Genetics Inc Stock (IRD) Company Profile
Name
Opus Genetics Inc
Sector
Industry
Phone
248-681-9815
Address
8 DAVIS DRIVE, DURHAM
Compare IRD vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRD
Opus Genetics Inc
|
4.67 | 342.77M | 14.20M | -49.59M | -35.25M | -0.8424 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Opus Genetics Inc Stock (IRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-16-26 | Initiated | Oppenheimer | Outperform |
| Jan-20-26 | Initiated | BTIG Research | Buy |
| Dec-10-25 | Initiated | B. Riley Securities | Buy |
| Nov-25-25 | Initiated | Piper Sandler | Overweight |
| Oct-29-25 | Initiated | Wedbush | Outperform |
| Oct-16-25 | Initiated | Chardan Capital Markets | Buy |
| Apr-11-25 | Initiated | Craig Hallum | Buy |
| Nov-13-24 | Resumed | H.C. Wainwright | Buy |
View All
Opus Genetics Inc Stock (IRD) Latest News
Balyasny Asset Management L.P. Expands Opus Genetics Inc (IRD) S - GuruFocus
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Opus Genetics stock maintains buy rating ahead of trial data By Investing.com - Investing.com Canada
Citizens reiterates Opus Genetics stock rating ahead of trial data - Investing.com
Citizens reiterates Opus Genetics stock rating ahead of trial data By Investing.com - Investing.com India
Wall Street Zen Upgrades Opus Genetics (NASDAQ:IRD) to "Hold" - MarketBeat
IRD Q2 2026 Earnings: Narrower-than-Expected Loss of -$0.14 Beats Estimates, Though Shares Slip 2.96%Profitability Analysis - vinanet.vn
Opus Genetics (NASDAQ:IRD) Rating Increased to Hold at Zacks Research - MarketBeat
Opus Genetics Q3 EPS Lifted by Brookline Capital Markets - MarketBeat
Brokers Set Expectations for Opus Genetics FY2030 Earnings - MarketBeat
Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright - MarketBeat
Opus Genetics, Inc. (NASDAQ:IRD) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How FDA Alignment Is Shaping Opus Genetics' OPGx-LCA5 Development Strategy - Clinical Leader
Opus Genetics completes phase 3 enrollment for OPGx-LCA5 gene therapy - Glance by Eyes On Eyecare
Opus Genetics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Opus Genetics Inc (IRD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Opus Genetics (IRD) Gets a Buy from RBC Capital - The Globe and Mail
Piper Sandler Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Opus Genetics Inc (IRD) Significantly Overvalued After Q2 Ear - GuruFocus
Opus Genetics (IRD) Q1 2026 Earnings: Deep EPS Miss Heightens Scrutiny on Clinical-Stage SpendingRevenue Beat Analysis - vinanet.vn
OPUS GENETICSMAY OFFER AND SELL UP TO $300 MLN OF SECURITIESSEC FILING - Moomoo
Opus Genetics (NASDAQ:IRD) Upgraded at Wall Street Zen - MarketBeat
IRD Maintained by RBC Capital -- Price Target Lowered to $9.00 - GuruFocus
A. G. P. Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $9 - Moomoo
A Quick Look at Today's Ratings for Opus Genetics(IRD.US), With a Forecast Between $9 to $10 - Moomoo
Opus GeneticsMay Offer And Sell Up To $300 Million Of SecuritiesSEC Filing - TradingView
RBC Adjusts PT on Opus Genetics to $9 From $10, Maintains Outperform Speculative Risk Rating - marketscreener.com
Opus Genetics (NASDAQ: IRD) sets $300M shelf and $125M ATM stock plan - Stock Titan
Opus Genetics earnings beat by $0.02, revenue fell short of estimates - Investing.com Canada
Opus Genetics (NASDAQ:IRD) Releases Earnings Results - MarketBeat
Opus Genetics, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.14) — 10-Q Summary - TradingView
Opus Genetics (Nasdaq: IRD) hit by $73.6M loss, rising warrant costs - Stock Titan
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update - The Manila Times
Opus Genetics Q2 revenue falls and misses estimates - TradingView
IRD: Gene therapy pipeline advances with strong cash position and key clinical milestones ahead - TradingView
Opus Genetics Reports Q2 2026 Results and Advances Multiple IRD Gene Therapy Programs with OPGx-BEST1 Data Expected in September - Quiver Quantitative
Opus Genetics reports Q2 2026 results: $0.8M revenue, $8.1M net loss, $88.8M cash - TradingView
Opus Genetics Completes Phase 3 Enrollment for AAV Gene Therapy OPGx-LCA5 - BioPharm International
Opus Genetics (IRD) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG Maintains Opus Genetics(IRD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Opus Genetics completes enrollment in LCA5 gene therapy trial - Investing.com
Opus Genetics completes enrollment in LCA5 gene therapy trial By Investing.com - Investing.com South Africa
Opus Genetics Completes Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 For LCA5-Associated Inherited Retinal Disease - marketscreener.com
Opus Genetics, Inc. $IRD Shares Sold by Perceptive Advisors LLC - MarketBeat
Opus Genetics, Inc. Revenue Breakdown – NASDAQ:IRD - TradingView
Opus Genetics (IRD) Slides 3.4% to $3.71 as Gene Therapy Stock Presses Key SupportIV Contraction - vinanet.vn
Opus Genetics (IRDC) Q1 2026 Earnings: Wide EPS Miss Reflects Pre-Revenue R&D InvestmentPre-Announcement Alert - vinanet.vn
Opus Genetics, Inc. Revenue Breakdown – FWB:R3X1 - TradingView
Form 4 Opus Genetics Inc For: 27 July By Investing.com - Investing.com India
Opus Genetics Inc (IRD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Opus Genetics Inc Stock (IRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opus Genetics Inc Stock (IRD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| YERXA BENJAMIN R | President |
Jul 23 '26 |
Sale |
2.97 |
7,429 |
22,064 |
704,106 |
| SCHACHLE JOSEPH K | Chief Operating Officer |
Jul 23 '26 |
Sale |
2.94 |
4,644 |
13,653 |
291,440 |
| Magrath George | Chief Executive Officer |
Jul 23 '26 |
Sale |
2.95 |
9,475 |
27,926 |
1,731,869 |
| Gagnon Robert E. | Chief Financial Officer |
Jul 23 '26 |
Sale |
2.95 |
7,783 |
22,942 |
584,375 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):